known to cause systemic hypotension, bradycardia, pulmonary artery hypotension or hypertension, thrombocytopenia, leukopenia, and declines in oxygen consumption. Increased thromboxane and prostacyclin activity has been reported after protamine administration in a porcine experimental model, and indomethacin has been reported to lessen many of the protamine-related hemodynamic responses [l-3] . The present investigation was designed to assess contributions of the arachidonic acid pathway to the effects of protamine reversal of heparin anticoagulation in an established canine experimental model and to specifically define the role of a thromboxane synthetase inhibitor and a cyclooxygenase inhibitor on usual protamine-related phenomenon.
METHODS
Twenty-four adult mongrel dogs, mean weight 22.5 kg, were anesthetized with pentobarbital sodium 30 mg/kg, mechanically ventilated to maintain arterial blood gases within physiologic range, and hydrated with lactated Ringers solution as a 20 ml/kg bolus followed by a continuous infusion of 10 ml/kg/hr for the duration of the experiment. Three pretreatment regimens were investigated. Group I control dogs (n = 8) received intravenous infusions of saline, Group II dogs (n = 8) received the specific thromboxane synthetase inhibitor U63,557A (Upjohn, Kalamazoo, MI) 30 mg/kg intravenously over 5 min, and Group III dogs (n = 8) received indomethacin (Spectrum Chemical, Gardenia, CA) 10 mg/kg intravenously over 5 min. Twenty minutes following completion of the pretreatment infusions, animals were anticoagulated with intravenous administration of beef-lung heparin, 150 IU/kg. Thirty minutes later protamine sulfate was administered as a bolus, 1.5 mg/kg over 10 set (Fig. 1) .
Oxygen saturations were assessed continuously using Oximetric Swan-Ganz catheters (Oximetrix, Mountain View, CA). Measurements included systemic mixed venous saturation (S,O,) by a catheter inserted in the pulmonary artery using a femoral vein approach, systemic arterial saturation (S,O,) by a catheter inserted into the abdominal aorta using a femoral artery approach, and Hemodynamic measurements were made at 15-set intervals for 1 min prior to protamine reversal of heparin anticoagulation, at 15-set intervals for the first 3 postreversa1 min, and subsequently at 5, 10, 20, and 30 min postreversal.
Cardiac outputs were measured as rapidly as possible, such that one measurement was made approximately every 30 set during the first 3 postreversal min and thereafter at 5, 10, 20, and 30 min. Platelet counts and white blood cell counts, using a hand hemocytometer, were determined at baseline, 3 min after pretreatment, immediately prior to protamine administration, and thereafter at 3, 5, and 30 min postreversal. Adequate anticoagulation and its reversal were documented by measuring activated clotting times (ACT, Hemochron, Edison, NJ). Prostacyclin was measured as its stable metabolic degradation product, 6-keto-PGF,,, and thromboxane was measured as its stable degradation product, TxB,. These prostanoids were measured at baseline, 3 min following completion of pretreatment, immediately prior to protamine administration, and at 1,3, and 30 min postreversal. Assays were undertaken in aortic, femoral venous, and left atria1 blood samples, the latter reflecting pulmonary blood. Prostacyclin was determined by RIA with a tritiated-labeled tracer (New England Nuclear, Boston, MA) having limited cross-reactivity with other prostaglandins (PGE,, 2.5%; PGF,,, 0.3%; PGE,, 0.2%; PGF,,, 0.05%; and TxB,, ~0.3%). Thromboxane was also measured with RIA using a tritiated tracer, having little cross-reactivity with other prostaglandins (PGD,, 1.0%; PGD,, 0.32%; PGF,,, 0.04%; and PGF,,, 0.04%). Prostanoid assays were performed in duplicate. To determine if elevations in prostacyclin levels after protamine observed in the present study resulted from the protamine administration alone, or from the accompanying hypotensive response, another group of 8 animals was studied. They were monitored in the exact same fashion as the previous 24 dogs with the administration of nitroprusside at an infusion rate producing a hypotensive response parallel to that produced by protamine reversal of heparin. Prostacyclin and thromboxane levels were measured in these dogs. These animals were not given heparin or protamine, only nitroprusside.
Platelet aggregation studies were conducted in all study groups before and after pretreatment.
Plateletrich plasma (PRP) was prepared by centrifugation of venous blood at 2OOg for 10 min, and platelet-poor plasma (PPP) was prepared by centrifugation of the supernatant at 1OOOg for an additional 10 min. PRP (450 ~1) was then stimulated by addition of 2 X 10e5 M ADP, and aggregation was observed after a 3-min period in a platelet aggregometer (Sienco, Turkey Creek, CO), with PRP considered as 0% transmission and PPP as 100% transmission.
Platelet aggregation measurements were made in duplicate.
Animal care complied with the Principles of Laboratory Animal Care and the Guide for the Care and Use of Laboratory Animals (NIH Publication No. 80-23, revised 1985). Statistical analyses included ANOVA and unpaired two-tailed t tests for parametric data, KruskalWallis and Wilcoxon's rank sum for nonparametric data, and correlation statistics when appropriate.
RESULTS
Baseline values for blood pressure, heart rate, and pulmonary artery pressures were statistically similar between the three groups indicative of steady-state conditions at the time of the protamine administration with no adverse influence by the saline, U63,557A, or indomethacin. Significant differences in blood pressure between the three groups were noted from 75 set to 10 min following protamine administration (Fig. 2) . Group III indomethacin-pretreated dogs attenuated the hypotensive response, when compared to Group II U63,557A pretreated dogs (P < O.Ol), with maximum declines of -8 + 27 and -56 + 24 mm Hg occurring in these two groups, respectively, and a -23 -f 33 mm Hg decline occurring in Group I control dogs. Heart rate differences were noted at 90, 120, and 150 to 165 set and at 5 and 10 min postreversal (Fig. 3) , with maximum declines being significantly less in Group III indomethacin-pretreated animals (-9 k 17 beats/min) compared to Group II U63,557A-pretreated dogs (-30 +-29 beats/min). Group differences in pulmonary artery systolic pressure occurred 165 set to 10 min postreversal, and differences in pulmonary artery diastolic pressure occurred 75 set to 10 min postreversal.
Although increases in pulmonary artery diastolic pressures affected Group I control dogs, Similarly, more severe declines in carotid artery flow occurred with Group II U63,557A pretreatment (-26 +-27%) compared to Group I controls (-14 + 26%) or Group III indomethacin pretreatment (-14 +. 28%).
Systemic mixed venous oxygen saturations differed at 30,120, and 150 set to 10 min postreversal, being statistically different between Groups I and II (P < 0.05) and Groups II and III (P -C 0.05). Maximal declines were -3 _t 8% in Group III indomethacin-pretreated dogs, -4 f 6% in Group I control dogs, and -18 2 19% in Group II U63,557A-pretreated dogs. Jugular venous oxygen saturations were also different between groups at 120 set and at 10 and 20 min postreversal.
No differences in systemic arterial oxygen saturations were observed between these groups.
Systemic oxygen consumption, although not statistically different among pretreatment groups (Fig. 5) , exhibited greater declines in Group II animals receiving U63,557A (-36 f 29%, 75 to 90 set postreversal) than in Group I control dogs (-17 + 24%, 105 to 120 set postreversal) or Group III dogs pretreated with indomethacin (-15 -t 22%, 75 to 90 set postreversal).
On the contrary, although not statistically different, maximum declines in cerebral oxygen consumption (Fig. 5) in Group I animals of -32 f 40% and Group III dogs of -25 +-24% were not matched by similar declines in Group II dogs receiving U63,557A, where actual increases were observed. Platelet count declines were pronounced in all groups, with maximum declines of -54 + 21% in Group I control dogs, -55 f 10% in Group II U63,557A-pretreated animals, and -52 + 18% in Group III indomethacin-pretreated dogs. White blood cell declines were more marked with Group II U63,557A pretreatment (-40 f 15%) than in Group I controls (-7 + 27%) or with Group III indomethacin pretreatment (-27 + 18%). Prostacyclin ( Fig. 6 ) and thromboxane ( Fig. 7 ) levels were significantly different in the study groups. Three minutes following pretreatment, prostacyclin levels fell most with Group III indomethacin pretreatment (-35 f 24, -45 +-18, and -41 + 18% within aortic, venous, and pulmonary samples, respectively), compared to similar measurements in Group I controls (-9 f 10, -7 -+ 23, and -13 f 15%) and with Group II U63,557A pretreatment (+48 + 20, +46 + 31, and +46 f 45%). One minute after protamine reversal, Group III indomethacin pretreated dogs exhibited less prostacyclin elevations in aortic and pulmonary samples than in Group I or II animals (P < 0.05) with actual declines observed in Group III. Maximal elevation in prostacyclin of +576 f 1264% was found in Group II aortic blood. Group III indomethacin pretreatment, in comparison to Group I or II, resulted in significantly less elevation in prostacyclin 3 min after protamine reversal within venous and pulmonary samples (P < 0.05), whereas at 30 min, differences occurred in all samples (aortic, venous, and pulmonary) between Group III indomethacin-pretreated dogs and Group I and II dogs (P < 0.05), with declines in prostacyclin in Group III animals.
Thromboxane levels 3 min after pretreatment declined most with Group III indomethacin pretreatment, were slightly less in Group II U63,557A-pretreated animals, and were elevated in Group I controls. Significant group differences in TxB, were noted only in venous samples at 1,3, and 30 min postreversal (P ring in Group I controls 3 min postreversal, in contrast to a -11 + 19% decline in Group II U63,557A-pretreated dogs (P < 0.01) and a -20 f 16% decline in Group III indomethacin-pretreated dogs (P -c 0.01).
Elevations of prostacyclin in aortic, venous, and pulmonary samples correlated well with declines in blood pressure at 1 min after protamine administration (r = 0.53, 0.52, and 0.53, respectively; P G O.Ol), as well as at 3 min postreversal (r = 0.53,0.70,0.60, respectively; P < 0.01). No significant correlations were found 30 min postreversal. No correlation existed between thromboxane elevations and declines in blood pressure. Correlations between prostacyclin elevations and oxygen consumption declines were found to be significant only in aortic and venous samples 3 min postreversal (r = 0.46, 0.43; P < 0.05). No significant correlations existed between thromboxane elevations and oxygen consumption. Changes in thromboxane and prostacyclin activity were not correlated with cerebral oxygen consumption changes. Finally, correlations between prostacyclin elevations and reductions in pulmonary artery systolic or diastolic pressures occurred at all time periods, whereas only one isolated correlation between thromboxane and elevations in pulmonary artery diastolic pressure occurred in venous blood 3 min postreversal (r = 0.48; P < 0.05).
Platelet aggregation revealed a 10% decline in Group I control animals between the baseline sample and the sample obtained following pretreatment (15.9 to 14.3%), a 40% decline in Group II dogs receiving U63,557A (13.9 to 8.4%), and a 32% decrease in Group III animals receiving indomethacin (14.7 to 10%). Baseline aggregation values were low, perhaps being an effect of the sodium pentobarbital anesthetic [4] .
The 8 animals given nitroprusside exhibited a -65 mm Hg drop in blood pressure 3 min after infusion of this agent began. Declines in prostacyclin were observed at 1, 3, and 30 min in aortic, venous, and pulmonary samples, but no significant correlations between declines in blood pressure and changes in prostacyclin levels were evident. This suggests that hypotension itself cannot explain the prostacyclin elevations. In these same animals, thromboxane levels were elevated after nitroprusside administration, but did not correlate with blood pressure changes.
DISCUSSION
Protamine reversal of heparin anticoagulation typically causes potentially adverse hemodynamic and hematologic responses, including vasodilation and hypotension, bradycardia, pulmonary artery hypertension or hypotension, thrombocytopenia, and leukopenia. Clinically, significant systemic arterial hypotension and pulmonary artery hypertension have been noted in 4% of cases and nearly 100 deaths have been attributed to the use of protamine [3, 5, 6] . Initial vasodilation occurring after protamine is manifested by a fall in systemic vascular resistance [ 71. During this early period of vasodilation, cardiac output increases in a compensatory fashion. However, approximately 60 set after vasodilation begins, cardiac output and oxygen consumption fall, suggesting a more direct central effect of protamine [8] . Several investigations, including recent work from our laboratory using an isolated rabbit heart model, suggest that protamine may produce direct dose-dependent depression of myocardial contraction [g-14] . However, few studies have addressed the mechanism for protamineinduced vasodilation and hypotension. The present in-JOURNAL OF SURGICAL RESEARCH: VOL. 50, NO. 5, MAY 1991 vestigation strongly supports the tenet that prostacyclin generation is associated with the hypotensive and vasodilatory effects of protamine administration.
The nature of changes in arachidonic acid pathway metabolites during protamine reversal of heparin has been examined by others. In a porcine experimental model, at the conclusion of a 3-min protamine infusion (2 mg/kg), there was a 35 mm Hg drop in mean arterial blood pressure, an increase in mean pulmonary artery pressure of 17 mm Hg, a decrease in left ventricular end diastolic pressure, and a concomitant decrease in arterial and mixed venous PO, [ 11. At the same time, thromboxane levels increased 460%, prostacyclin levels increased X0%, and prostaglandin F,, levels increased 220%, with its major degradation product 13-14-dihydro-15-keto prostaglandin F,, (KH, PGF,,) increasing 690%. There was little difference in arterial and mixed venous plasma prostanoid activities. In this same study, indomethacin (10 mg/kg), given intravenously before administration of heparin and protamine, blocked these changes with no evidence of hypotension, pulmonary artery hypertension, blood gas changes, or prostanoid elevation. These former investigators concluded that activation of the arachidonic acid cascade occurs in the lungs, that the increased pulmonary vascular resistance can best be explained by liberation of the vasoconstricting prostanoids TxA, and PGF,, , and that prostacyclin may be partially responsible for the low systemic vascular resistance noted.
Conzen and associates studied the TxA, receptor antagonist BM 13.177 (10 mg/kg) infused 5 min before protamine administration and indomethacin (10 mg/kg) given before heparin and protamine [2] . In the group given BM 13.177, levels of TxB, and PGF,, remained similarly elevated after protamine as in control pigs, but significant hemodynamic alterations were not observed. In fact, a 21% decline in pulmonary vascular resistance occurred 5 min after the completion of the protamine infusion.
No hemodynamic changes or alterations in plasma prostanoid levels occurred after protamine administration in animals pretreated with indomethacin. These authors concluded that most of the adverse hemodynamic effects associated with protamine were mediated by TxA,. However, the model utilized produced little hypotension with at most an 11% decrease in mean arterial blood pressure 5 min after the termination of protamine infusion. This would not have represented significant hypotension as reflected in our study by maximum changes of -45% in Group II U63,557A-treated dogs and -21% in control animals. Such differences most likely relate to species differences. The slight decreases in pulmonary artery pressure and pulmonary vascular resistance in these pigs pretreated with BM 13.177 were thought likely to be related to increased production of prostacyclin, as evident by the 102% increase in 6-keto-PGF,, in this group compared to the 63% in- It is believed that this process occurs in contiguous tissues, by the isomerase activity of plasma albumin, or from leukocyte production, respectively, leading to an increased load of vasodilator prostaglandins. In fact, 3 min after infusion of U63,557A, prostacyclin levels were increased 48, 46, and 46% in artery, vein, and pulmonary blood samples, respectively, in contrast to decreases of -35, -45, and -41% in the same blood samples after indomethacin pretreatment.
The strong statistical correlations between prostacyclin elevations and blood pressure declines at 1 and 3 min after protamine administration support the probable existence of prostanoid shunting in this setting.
During thromboxane synthetase inhibition, the endoperoxide precursors PGG, and PGH, may occupy and activate the thromboxane receptor [32] . Using the thromboxane receptor antagonist SQ 29,548 (Squibb, Princeton, NJ), we observed no inhibition in the magni-tude of protamine sulfate-induced adverse hemodynamic responses in the same canine model used in the current investigation (unpublished observations). This 11. lends further credence to our conclusion that thromboxane is not the major mediator of protamine-induced hypotension and vasodilation.
12.
Protamine causes declines in oxygen consumption both in uiuo [8] and in vitro [33] , most likely because of 13. its polycationic character [18] . One would not expect either U63,557A or indomethacin pretreatment to completely block these metabolic changes. Indomethacin 14. pretreatment did attenuate to some degree the decline in systemic oxygen consumption, suggesting that a portion of the decline in oxygen consumption is related to its 15. hemodynamic effect rather than to its metabolic effect, as has been shown previously [24] . However, it is clear that the decline in oxygen consumption relates in part to 1s. direct metabolic toxic effects of the drug on cellular elements and is unrelated to systemic hypotension, vasodilation, or pulmonary artery hypertension.
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